Hydroxycarbamid 1 A Pharma

Hydroxycarbamide, the active ingredient in Hydroxycarbamid 1 A Pharma, is an antimetabolite presented as an oral tablet for systemic use. It is employed in the management of myeloproliferative disorders, sickle cell disease and chronic myeloid leukemia, targeting abnormal cell proliferation.

GNH USA supplies Hydroxycarbamid 1 A Pharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides regulatory‑approved batches to meet global demand. Customer support includes documentation assistance and reliable logistics for timely delivery.

Hydroxycarbamide is used in several hematologic conditions that involve abnormal cell proliferation. - Myeloproliferative disorders: reduces excessive blood cell production and helps control disease activity. - Sickle cell disease: decreases frequency of painful crises and lowers need for blood transfusions. - Chronic myeloid leukemia: contributes to cytoreduction and can be part of combination therapy to achieve disease control.

Hydroxycarbamide may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea or vomiting: mild gastrointestinal upset that may resolve spontaneously. - Bone marrow suppression: temporary reduction in white cells, platelets or red cells. - Skin changes: hyperpigmentation, rash or dry skin. - Hair loss: reversible alopecia that regrows after stopping therapy. - Fatigue: persistent tiredness affecting daily activities. - Mouth ulcers: painful sores in the oral cavity.

Serious or Rare Side Effects: - Severe neutropenia: marked drop in neutrophils increasing infection susceptibility. - Acute renal failure: sudden loss of kidney function requiring monitoring. - Pulmonary toxicity: interstitial lung disease presenting with cough or shortness of breath. - Leg ulcers: chronic painful skin lesions, often on lower limbs. - Teratogenic effects: potential to cause birth defects if exposure occurs during pregnancy. - Hypersensitivity reactions: anaphylaxis or severe skin reactions such as Stevens‑Johnson syndrome.

When using hydroxycarbamide, several precautions should be observed to minimize risks and ensure safe therapy. - Monitor blood counts: perform regular CBC to detect marrow suppression. - Assess renal function: check serum creatinine before initiation and periodically. - Evaluate liver enzymes: monitor hepatic function during treatment. - Avoid use in known hypersensitivity: discontinue if severe allergic reaction occurs. - Pregnancy and lactation: contraindicated unless benefits outweigh risks; discuss with specialist. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and light.

Hydroxycarbamide can interact with other medicines, altering its effectiveness or increasing toxicity.

Major Interactions (Avoid): - Antiretroviral protease inhibitors: may increase hydroxycarbamide plasma levels. - Azathioprine: additive bone marrow suppression. - Live vaccines: heightened risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - Allopurinol: may enhance hematologic toxicity; monitor blood counts. - NSAIDs: increase risk of renal impairment. - Phenytoin: may reduce hydroxycarbamide efficacy; adjust dose if needed.